On May 22, 2025 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present data from more than 19 studies, including a landmark plenary session on the Phase 3 SERENA-6 trial, demonstrating the critical role of Guardant liquid biopsy tests in cancer screening, therapy selection and recurrence monitoring at the 2025 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago (Press release, Guardant Health, MAY 22, 2025, View Source [SID1234653343]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Featured presentations demonstrate the use of Guardant’s portfolio of blood tests, real-world data and AI to identify genomic and epigenomic biomarkers that can inform treatment decisions across a variety of solid tumor types. Studies also highlight new capabilities of the Guardant360 Liquid test to identify molecular tumor type in carcinomas of unknown primary and confirm the absence of actionable biomarkers, both enabled by the Guardant Infinity smart liquid biopsy platform, Presentation highlights include:
Abstract LBA4 plenary session demonstrating the use of the Guardant360 CDx test in detecting emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2- advanced breast cancer in the Phase 3 SERENA-6 trial
Abstract 3504 oral session evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection using Guardant Reveal in stage III colon cancer patients after surgery and prior to adjuvant therapy. This study showed a robust prognostic utility of Reveal to identify patients with poorer disease-free and overall survival in a large clinical trial cohort of over 2,000 patients with a median follow-up of 6.1 years.
Abstract 3584 providing analytic and clinical validation of an algorithm to predict the absence of actionable mutations in ctDNA-negative colorectal and non-small cell lung cancer samples, utilizing genomic and epigenomic profiling with the Guardant360 Liquid test.
Abstract 3073 demonstrating application of an epigenomic-based classifier to identify tumor type on liquid biopsy in cancer of unknown primary origin. Study provides validation data for the new molecular tumor type feature of Guardant360 Liquid utilizing DNA methylation signatures across thousands of cancer-specific differentially methylated regions for 14 cancer types.
"The data we and our research colleagues are presenting at ASCO (Free ASCO Whitepaper) demonstrate the clear and growing contribution of liquid biopsy in transforming cancer care and helping to improve patient outcomes," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "The SERENA-6 study in particular highlights how we are pushing the boundaries of what can be done with liquid biopsy in characterizing disease and potential drug efficacy, providing insights that could potentially change clinical practice."
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO (Free ASCO Whitepaper) 2025 can be found on the ASCO (Free ASCO Whitepaper) website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit ASCO (Free ASCO Whitepaper) booth #25077.
Guardant Health and collaborator presentations at ASCO (Free ASCO Whitepaper)
Abstract/Poster
Title (Hall A unless otherwise noted)
Product
Friday, May 30, 2:45 pm – 5:45 pm CT (Arie Crown Theater, Live Stream)
3504
Oral Abstract Session: Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147)
Guardant Reveal
Saturday, May 31, 9:00 am – 12:00 pm CT
3584/253
Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA
Guardant360 Liquid
4200/490
Circulating tumor DNA-based genomic profiling and real-world outcomes in cancer of unknown primary (CUP)
Guardant360 Liquid
GuardantINFORM
Saturday, May 31, 1:30 pm – 4:30 pm CT
8528/8
Genomic and circulating tumor DNA landscape in young-onset non-small cell lung cancer
Guardant360 Liquid
8642/122
Use of targeted therapy, healthcare costs, and survival with large panel testing, narrow testing, or no molecular testing in patients with metastatic non-small cell lung cancer (mNSCLC)
Guardant360 Liquid
Guardant360 CDx
10550/275
Validation of a plasma cell-free DNA methylation-based multi-cancer detection test
Shield MCD
Sunday, June 1, 2:41 pm – 2:53 pm CT (Plenary Session, Hall B1, Live Stream)
LBA4
Oral Clinical Science Symposium: Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial
Guardant360 CDx
Sunday, June 1, 4:30 pm – 6:00 pm CT (Arie Crown Theater, Live Stream)
1012
Oral Clinical Science Symposium: Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial
Guardant OMNI
Monday, June 2, 9:00 am – 12:00 pm CT
1052/31
Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab
Guardant Reveal
1075/54
Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance
Guardant360 Liquid
5052/251
Evaluating the prognostic utility of cell-free (cf)DNA tumor fraction (TF) in metastatic castration-resistant prostate cancer (mCRPC)
Guardant360 Liquid
5053/252
Real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) and AR T878A alterations treated with enzalutamide
GuardantINFORM
5077/276
Real-world prevalence of homologous recombination repair alterations (HRRa) and poly (ADP-ribose) polymerase inhibitor (PARPi) use/outcomes in patients (pts) with metastatic prostate cancer (mPC) by race and ethnicity
GuardantINFORM
5086/285
Association between epigenomic biomarkers and baseline clinical characteristics in patients with mCRPC treated with rucaparib in TRITON2
Guardant Infinity
Monday, June 2, 1:30 pm – 4:30 pm CT
3073/388
Application of an epigenomic-based classifier to identify cancer signal of origin on liquid biopsy in cancer of unknown primary cases
Guardant360 Liquid
3074/389
HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay
Guardant360 Liquid
Tuesday, June 3, 8:30 am CT
5512
Oral Abstract Session: Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA
Guardant Infinity
Online Abstracts
e20536
Accelerating treatment decisions with liquid biopsy NGS in non-small cell lung cancer
Guardant360 Liquid
e13084
Targeted agents for the treatment of hormone receptor–-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+/HER2- MBC) with co-alterations in ESR1 and AKT pathway: A retrospective analysis
Guardant360 Liquid